|
David A. Karlin M.D. joined the Company as senior vice president of clinical development and regulatory affairs in July 2005. Prior to that he served as vice president of clinical research at Cellegy Pharmaceuticals Inc. Dr. Karlin's experience in the biotech and pharmaceutical industry also includes positions as vice president of clinical development for Genteric Inc. a privately-held company specializing in gene therapy and senior medical director at Matrix Pharmaceuticals Inc. an oncology therapeutics development company. Dr. Karlin has also served as vice president for clinical research and medical director at SciClone Pharmaceuticals Inc. and held various positions at Syntex Corporation including director of medical research. Before joining the pharmaceutical industry Dr. Karlin was an associate professor at Temple University School of Medicine and an assistant professor at the University of Texas M.D. Anderson Hospital and Tumor Institute. He received his M.D. from the University of Chicago and completed his residency in internal medicine at the University of Michigan and a fellowship in gastroenterology and gastrointestinal oncology at the University of Chicago. He holds a B.S. in Biology from the University of Illinois. | 